These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Recommendations proposed for adenovirus gene therapy trials in the UK. Nevin NC; Spink J Mol Med Today; 2000 Dec; 6(12):461. PubMed ID: 11187936 [No Abstract] [Full Text] [Related]
3. A tumultuous year for gene therapy. Verma IM Mol Ther; 2000 Nov; 2(5):415-6. PubMed ID: 11082313 [No Abstract] [Full Text] [Related]
4. Death but one unintended consequence of gene-therapy trial. Sibbald B CMAJ; 2001 May; 164(11):1612. PubMed ID: 11402803 [No Abstract] [Full Text] [Related]
5. Gene therapy on trial. Marshall E Science; 2000 May; 288(5468):951-7. PubMed ID: 10841710 [No Abstract] [Full Text] [Related]
7. Studies illuminate cause of fatal reaction in gene-therapy trial. Stephenson J JAMA; 2001 May 23-30; 285(20):2570. PubMed ID: 11368717 [No Abstract] [Full Text] [Related]
8. Tighter watch urged on adenoviral vectors...with proposal to report all 'adverse events'. Smaglik P Nature; 1999 Dec; 402(6763):707. PubMed ID: 10617181 [No Abstract] [Full Text] [Related]
9. Gene-therapy trials must proceed with caution. Nature; 2016 Jun; 534(7609):590. PubMed ID: 27357758 [No Abstract] [Full Text] [Related]
10. General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination. Baldo A; van den Akker E; Bergmans HE; Lim F; Pauwels K Curr Gene Ther; 2013 Dec; 13(6):385-94. PubMed ID: 24195604 [TBL] [Abstract][Full Text] [Related]
17. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther; 2002 Jan; 13(1):3-13. PubMed ID: 11779411 [No Abstract] [Full Text] [Related]